<DOC>
	<DOCNO>NCT00881842</DOCNO>
	<brief_summary>Influenza ( flu ) viruses change continuously , therefore also part virus use influenza vaccine vary year year . In Europe , manufacturers/marketing holder vaccine require involved ongoing clinical trial present result competent authority year . The current study phase IIIa clinical trial commercially available vaccine ( Influvac® ) supply pre fill syrinx . It part ongoing clinical trial program Influvac® do ass immunogenicity safety tolerability next season 's trivalent influenza subunit vaccine two group subject good health : subject age &gt; = 18 &lt; = 60 year subject &gt; = 61 year age ( elderly ) .</brief_summary>
	<brief_title>Annual Study Investigate Inactivated Subunit Influenza Vaccine Due New Virus Strains 09/10 Season</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Willing able give inform consent able adhere protocol require study procedure . Men woman age &gt; = 18 &lt; = 60 year &gt; = 61 year age day study vaccination . Being good health judge medical history , physical examination clinical judgment investigator . Exclusion Criteria Known allergic egg , chicken protein , gentamicin constituent vaccine . A serious adverse reaction previous ( influenza ) vaccination . Presence significant condition may prohibit inclusion determine investigator . Having receive vaccination influenza within previous six month study vaccination plan vaccination study period . A history GuillainBarré syndrome active neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>CHMP criterion</keyword>
</DOC>